Vice President, Pharmacy Benefits, SelectHealth, Murray, UT. Email:
Am J Manag Care. 2018 Oct;24(19 Suppl):S428-S433.
The prevalence of peanut allergies, the most common food allergy in children, has tripled in the past 2 decades. Today, up to 2.5% of the pediatric population has been diagnosed with a peanut allergy. Peanut allergies result in significant medical, out-of-pocket, and opportunity costs to payers, parents, and employers. They are also a leading cause of food allergy-related deaths in children. Although there is evidence that peanut oral immunotherapy may be effective in reducing the severity of the allergy, such approaches require a long intervention with no standardized protocol available. The introduction of biologic compounds to treat peanut allergies has the potential to revolutionize how these patient cases are managed. Their anticipated high cost, however, raises several issues for payers as to how to integrate these new therapies into formularies and treatment continuums.
花生过敏的患病率在过去 20 年内增长了两倍，成为儿童最常见的食物过敏。如今，多达 2.5%的儿科人群被诊断出患有花生过敏症。花生过敏给支付方、家长和雇主带来了巨大的医疗、自付和机会成本。它也是导致儿童食物过敏相关死亡的主要原因。虽然有证据表明花生口服免疫疗法可能有效减轻过敏的严重程度，但这些方法需要长期干预，目前尚无标准化方案。生物化合物的引入有可能彻底改变这些患者的管理方式。然而，它们预期的高成本给支付方提出了如何将这些新疗法纳入处方和治疗方案的问题。
